ClinicalTrials.gg
CompletedNCT01607762Updated Apr 9, 2013

A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics

A Phase 1 interventional study of Aripiprazole and Quetiapine in Healthy, sponsored by Janssen Research & Development, LLC. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-04-09.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to compare capillary (the smallest of a body's blood vessels) and venous whole blood and plasma concentrations of 5 antipsychotics after given of a single oral, immediate-release dose to healthy participants.

Read the detailed description

This is a randomized (the study drug is assigned by chance), open-label (all people know the identity of the intervention), parallel-group (each group of patients will be treated at the same time), single-center study. Participants will be randomly assigned to 1 of 5 cohorts (groups) defined by the antipsychotic drug (aripiprazole, quetiapine, olanzapine, risperidone or paliperidone). Antipsychotics are drugs that are helpful in the treatment of psychosis and have a capacity to ameliorate thought disorders. Participants will enter the investigational site in the morning of Day -1 and stay until the morning of Day 2. Participants will return to the study site for subsequent assessments as per study's schedule. The total study length for a participant is approximately 26 days, except for participants receiving aripiprazole for whom the total study length is approximately 39 days.

02

Conditions studied

  • Healthy

Keywords

  • Healthy
  • Antipsychotics
  • Aripiprazole
  • Paliperidone
  • Risperidone
  • Quetiapine
  • Olanzapine
03

In context

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (weight [kg]/height2 [m]2) between 17 and 35 kg/m2 (inclusive), and body weight not less than 50 kg
  • If a woman, must be , surgically sterile, abstinent, or, if sexually active, be practicing an effective method of before entry and throughout the study
  • If a woman, must have negative pregnancy test at screening
  • If a man, must agree to use an adequate contraception method as deemed appropriate by the investigator and to not donate sperm during the study and for 3 months after receiving the study drug
  • Blood pressure between 90 and 140 mmHg systolic, inclusive, and no higher than 90 mmHg diastolic

Exclusion criteria

Exclusion Criteria:

  • History of or current medical illness or condition that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results
  • Clinically significant abnormal values for laboratorial tests
  • Use of any prescription or nonprescription medication (including vitamins and herbal supplements), except for paracetamol (acetaminophen), oral and hormonal replacement therapy, within 14 days before the study drug administration is scheduled
  • Positive test for alcohol or drugs of abuse at screening
  • Unable to swallow solid, oral dosage forms whole with the aid of water (participants may not chew, divide, dissolve, or crush the study drug)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Cohort A: Aripiprazole

    Drug: Aripiprazole

  • Experimental
    Cohort B: Quetiapine

    Drug: Quetiapine

  • Experimental
    Cohort C: Olanzapine

    Drug: Olanzapine

  • Experimental
    Cohort D: Risperidone

    Drug: Risperidone

  • Experimental
    Cohort E: Paliperidone

    Drug: Paliperidone

Interventions

  • Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg aripiprazole tablet will be administered after an overnight fast.

  • Type= exact number, unit= mg, number= 100, form= tablet, route= oral administration. A single oral dose of two 50-mg quetiapine tablets will be administered after an overnight fast.

  • Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg olanzapine tablet will be administered after an overnight fast.

  • Type= exact number, unit= mg, number= 1, form= tablet, route= oral administration. A single oral dose of a 1-mg risperidone tablet will be administered after an overnight fast.

  • Type= exact number, unit= mg, number= 3, form= tablet, route= oral administration. A single oral dose of a 3-mg paliperidone tablet will be administered after an overnight fast.

06

What researchers measure

Primary outcomes

  1. Aripiprazole concentration in venous and capillary plasma, venous and capillary whole blood

    Time frame: 16 time points over 408 hours postdose

  2. Quetiapine concentration in venous and capillary plasma, venous and capillary whole blood

    Time frame: 12 time points over 108 hours postdose

  3. Olanzapine concentration in venous and capillary plasma, venous and capillary whole blood

    Time frame: 12 time points over 108 hours postdose

  4. Risperidone concentration in venous and capillary plasma, venous and capillary whole blood

    Time frame: 12 time points over 108 hours postdose

  5. Paliperidone concentration in venous and capillary plasma, venous and capillary whole blood

    Time frame: 12 time points over 108 hours postdose

  6. Dehydroaripiprazole concentration in venous and capillary plasma, venous and capillary whole blood

    Time frame: 16 time points over 408 hours postdose

  7. 9 hydroxy-risperidone concentration in venous and capillary plasma, venous and capillary whole blood

    Time frame: 12 time points over 108 hours postdose

Secondary outcomes

  1. Incidence of adverse events as a measure of safety and tolerability

    Time frame: Approximately 26 days (Cohorts B, C, D, E), and approximately 39 days (Cohort A)

07

Study locations

1 site
  • Merksem, Belgium
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Apr 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2012
First posted
May 30, 2012
Start
Feb 2012
Primary completionActual
Apr 2012
CompletionActual
Oct 2012
Last update
Apr 9, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01607762
Responsible party
Sponsor
First posted
May 30, 2012
Start date
Feb 2012
Primary completion
Apr 2012
Completion
Oct 2012
Last update
Apr 9, 2013

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aripiprazole · Quetiapine · Olanzapine · Risperidone · Paliperidone

Start the discussion